Friday 6 November 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue: +10.9%
EPS: −351.9%
Free cash flow: −11.5%
Total debt: +3.28%

Quarter to September 2026, against a year earlier

169.01 9.19 −5.16%

Follow RGEN

Alert me

Market cap: $10.8B
P/E: 0.0×
Fwd P/E: −615×
Dividend yield: —
F-score: 6/9
Altman Z: 7.49
Beneish M: −2.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Repligen Corporation (RGEN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Repligen Corporation (RGEN) trades at a price to free cash flow of 170×. Over the past ten years it has ranged from 0.0× (December 2017) to 758× (June 2015); the current reading is higher than 69% of that period. That is above the Medical Instruments & Supplies industry median of 23.5× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RGEN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Repligen Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RGEN/metrics/price-to-free-cash-flow">Repligen Corporation (RGEN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	216×	158.14%
FY2024	83.7×	(37.25%)
FY2023	133×	24.26%
FY2022	107×	(64.84%)
FY2021	305×	9.95%
FY2020	278×	173.51%
FY2019	101×	(12.12%)
FY2018	115×	(2.22%)
FY2017	118×	(63.40%)
FY2016	323×	331.00%

Period	Price to free cash flow	Change
Sep 2026	193×	53.55%
Jun 2026	126×	5.13%
Mar 2026	120×	(44.50%)
Dec 2025	216×	60.73%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 758×

Ten-year median 128×

Current reading's percentile 69

Company	Price to free cash flow
SOLV Solventum Corporation compare	n/m
BAX Baxter International Inc. compare	11.6×
ALGN Align Technology, Inc. compare	16.8×
COO The Cooper Companies, Inc. compare	18.1×
AVTR Avantor, Inc. compare	23.3×
ATR AptarGroup, Inc. compare	31.0×
BLCO Bausch + Lomb Corporation compare	31.4×
TFX Teleflex Incorporated compare	125×
RGEN Repligen Corporation	170×
Medical Instruments & Supplies industry median	23.5×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Repligen Corporation (RGEN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RGEN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RGEN

Stockrow Weekly